Literature DB >> 25550829

Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma.

Wen-Ke Cai1, Jia-Ji Lin2, Gong-Hao He3, Hua Wang4, Jun-Hua Lu5, Guang-Shun Yang5.   

Abstract

To investigate the appropriate cutoff point of CA19-9 for prognosis and other potential prognostic factors that may affect survival of patients with hilar cholangiocarcinoma (HC) after radical surgery. 168 patients who had undergone radical surgery for hilar cholangiocarcinoma and resultant macroscopic curative resection (R0 and R1) were discreetly selected for analyses. Categorized versions were used in univariate model to determine the appropriate cutoff point of CA19-9. CA19-9 and other clinicopathologic factors were analyzed for influence on survival by univariate and multivariate methods. The strongest univariate predictor among the categorized preoperative CA19-9 measures was CA19-9 less than 150 IU/L (P = 0.000). In univariate analysis, tumor size, Bismuth-Corlette classification, portal vein invasion, Lymph node metastasis, resection margin and preoperative CA19-9 levels were identified as significant prognostic factors. In multivariable analysis, lymph node metastasis, resection margin and preoperative CA19-9 levels were independent prognostic factors. our results demonstrated that preoperative CA19-9 levels was also an independent prognostic factor for hilar cholangiocarcinoma, and the most discriminative cutoff point of CA19-9 for prognosis proved to be at 150 U/ml.

Entities:  

Keywords:  CA19-9; Hilar cholangiocarcinoma; cutoff point; lymph node metastasis; resection margin

Mesh:

Substances:

Year:  2014        PMID: 25550829      PMCID: PMC4270533     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  36 in total

1.  Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma.

Authors:  Noriaki Sagawa; Satoshi Kondo; Toshiaki Morikawa; Shunichi Okushiba; Hiroyuki Katoh
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Intrahepatic cholangiocarcinoma in Korea.

Authors:  H J Kim; S S Yun; K H Jung; W H Kwun; J H Choi
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

3.  Prognostic value of CA 19-9 serum course in pancreatic cancer.

Authors:  F Safi; W Schlosser; S Falkenreck; H G Beger
Journal:  Hepatogastroenterology       Date:  1998 Jan-Feb

4.  Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival.

Authors:  Q Cheng; X Luo; B Zhang; X Jiang; B Yi; M Wu
Journal:  Eur J Surg Oncol       Date:  2006-11-07       Impact factor: 4.424

5.  Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor).

Authors:  Sander Dinant; Michael F Gerhards; E A J Rauws; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik
Journal:  Ann Surg Oncol       Date:  2006-04-14       Impact factor: 5.344

6.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

7.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

8.  Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience.

Authors:  Manousos M Konstadoulakis; Sasan Roayaie; Ilias P Gomatos; Daniel Labow; Maria-Isabell Fiel; Charles M Miller; Myron E Schwartz
Journal:  Am J Surg       Date:  2008-05-07       Impact factor: 2.565

9.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

10.  Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer.

Authors:  Jan Harder; Oliver Kummer; Manfred Olschewski; Florian Otto; Hubert Erich Blum; Oliver Opitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10       Impact factor: 4.254

View more
  21 in total

1.  Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma.

Authors:  Pakkayanee Sudsarn; Thidarut Boonmars; Wipaporn Ruangjirachuporn; Nisana Namwat; Watcharin Loilome; Pranee Sriraj; Ratchadawan Aukkanimart; Wonkchalee Nadchanan; Songsri Jiraporn
Journal:  Pathol Oncol Res       Date:  2015-08-16       Impact factor: 3.201

2.  Correlation between metastatic lymph node ratio and prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Jian-Wei Zhang; Yun-Mian Chu; Zhong-Min Lan; Xiao-Long Tang; Ying-Tai Chen; Cheng-Feng Wang; Xu Che
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

3.  Modification and comparison of CT criteria in the preoperative assessment of hepatic arterial invasion by hilar cholangiocarcinoma.

Authors:  Guoqiang Dong; Kefeng Zhou; Anning Hu; Jian He; Qun Zhou; Qiongjie Zhu; Yudong Qiu; Liang Mao; Jun Chen
Journal:  Abdom Radiol (NY)       Date:  2020-11-07

4.  Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Nobuhiro Fujita; Takao Ohtsuka; Tomoharu Yoshizumi; Shinichi Aishima; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

5.  Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer.

Authors:  Gaya Spolverato; Fabio Bagante; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Emily Winslow; Clifford Cho; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

6.  Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma.

Authors:  Sven H Loosen; Fabian Benz; Jennifer Niedeggen; Maximilian Schmeding; Florian Schüller; Alexander Koch; Mihael Vucur; Frank Tacke; Christian Trautwein; Christoph Roderburg; Ulf P Neumann; Tom Luedde
Journal:  Clin Transl Med       Date:  2016-09-27

Review 7.  Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Authors:  Alice Boilève; Marc Hilmi; Matthieu Delaye; Annemilaï Tijeras-Raballand; Cindy Neuzillet
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

Review 8.  Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.

Authors:  Alan Kirwan; Marta Utratna; Michael E O'Dwyer; Lokesh Joshi; Michelle Kilcoyne
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

9.  Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma.

Authors:  Hai-Jie Hu; Hui Mao; Yong-Qiong Tan; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  Springerplus       Date:  2016-04-30

10.  Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.

Authors:  Peizhan Chen; Bin Li; Yan Zhu; Wei Chen; Xin Liu; Mian Li; Xiaohua Duan; Bin Yi; Jinghan Wang; Chen Liu; Xiangji Luo; Xiaoguang Li; Jingquan Li; Lijian Liang; Xiaoyu Yin; Hui Wang; Xiaoqing Jiang
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.